Purdue Pharma to present Butrans Transdermal System CIII clinical program data at PAINWeek 2010

Purdue Pharma L.P. will present data from the clinical program for Butrans™ (buprenorphine) Transdermal System CIII in a series of posters at PAINWeek®2010, September 8-10 in Las Vegas.

Butrans recently received marketing approval from the U.S. Food and Drug Administration and is expected to be commercially available in the U. S. during the first quarter of 2011.

The featured studies evaluated the safety and efficacy of Butrans in a variety of patient scenarios. They include:

  • The Efficacy and Safety of Buprenorphine Transdermal System in Patients with Moderate to Severe Low Back Pain: A Double-Blind Study: Deborah J. Steiner, MD; Catherine Munera, PhD; Martin E. Hale, MD; Steven R. Ripa, MD; Craig Landau, MD
  • The Efficacy and Safety of Buprenorphine Transdermal System in Opioid-Naïve Patients with Moderate to Severe Low Back Pain: A Double-Blind Study: Deborah J. Steiner, MD; Steve Sitar, MD; Warren Wen, PhD; Gosford Sawyerr, MS; Catherine Munera, PhD; Shau Yu Lynch, PhD; Steven R. Ripa, MD
  • Long-Term Use of Buprenorphine Transdermal System in Patients with Chronic Pain: Warren Wen, PhD; Catherine Munera, PhD; Bradley Dain, PhD; Steven R. Ripa, MD
  • Comparable Analgesic Efficacy of Buprenorphine Transdermal System in Patients Over and Under 65 Years Of Age: Warren Wen, PhD; Shau Yu Lynch, PhD; Catherine Munera, PhD; Steven R. Ripa, MD
  • A Randomized, Double-Blind Study Evaluating Conversion From Hydrocodone (HCD)/Acetaminophen (Vicodin®) to Buprenorphine Transdermal System in Patients with Osteoarthritis Pain: Steven R. Ripa, MD; Bill H. McCarberg, MD; Catherine Munera, PhD; Warren Wen, PhD; Craig J. Landau, MD
Source:

 Purdue Pharma L.P.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination amongst healthcare workers